This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Irwin R. Walker, MB, BS; William E. C. Wilson, MD; Daniel N. Sauder, MD; Ann M. Benger, MD; George Browman, MD
Department of Medicine McMaster University 1200 Main St W Hamilton, Ontario, Canada L8N 3Z5

Arch Dermatol. 1985;121(10):1240-1241.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In the January 1985 ARCHIVES, Levine et al¹ reported the occurrence of acral erythema during therapy for severe myelogenous leukemia. We have made similar observations and would like to contribute additional information.

The patients described by Levine et al were all receiving combination chemotherapy, and the authors did not ascribe the reaction to any single agent. Acral erythema is not a specific reaction to one agent and has been reported in patients given cytarabine,² doxorubicin,³ fluorouracil,³ and methotrexate⁴ alone. However, in the cases reported by Levine et al, the reaction was almost certainly to cytarabine, because acral erythema secondary to doxorubicin has been described only in association with constant infusions, which were not used in these cases. Furthermore, acral erythema is being noted with increasing frequency now that cytarabine is being given in higher dosages than those used in the past; we agree that the reaction is toxic and we suggest, with respect to cytarabine . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?